{"id":2589356,"date":"2025-12-23T12:05:05","date_gmt":"2025-12-23T17:05:05","guid":{"rendered":"https:\/\/www.valuewalk.com\/?p=2589356"},"modified":"2025-12-24T14:05:44","modified_gmt":"2025-12-24T19:05:44","slug":"how-this-stock-with-no-revenue-returned-more-than-17000","status":"publish","type":"post","link":"https:\/\/www.valuewalk.com\/news\/how-this-stock-with-no-revenue-returned-more-than-17000\/","title":{"rendered":"How This Stock with No Revenue Returned More Than 17,000%"},"content":{"rendered":"\n

A 17,000% gain with no revenue — how did this happen?<\/strong><\/p>\n\n\n\n

One of the most interesting and incredible stock stories of 2025 was the meteoric rise of a pharma stock with no revenue.<\/p>\n\n\n\n

The stock is Regencell <\/strong>Bioscience<\/strong> (NASDAQ:RGC), and it has returned an astronomical 17,000%-plus in 2025, with a market cap of about $11 billion.<\/p>\n\n\n\n

Regencell is a Hong Kong-based company that \u201cfocuses on research, development and commercialization of Traditional Chinese Medicine <\/strong>for the global treatment of neurocognitive disorder and degeneration,\u201d specifically attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD)<\/strong>.<\/p>\n\n\n\n

The company, according to its 20-F SEC filing<\/a>, is in the research and development stage and has not yet generated any revenue<\/strong> since inception \u2013 or since its IPO in 2021.<\/p>\n\n\n\n

\u201cWe have funded our operations to date primarily through proceeds from our initial public offering of our ordinary shares. We have no saleable products and have not generated any revenue from product sales<\/strong>,\u201d the filing says. We have incurred operating losses since our formation. We incurred total net losses of $3.58 million and $4.36 million<\/strong>, respectively, for the fiscal years ended June 30, 2025 and 2024.\u201d<\/p>\n\n\n\n

All losses have resulted from costs related to its development programs as well as general and administrative costs.<\/p>\n\n\n\n

\u201cWe expect to continue to incur research and development expenses in the future as we continue the advancement of our efficacy trials and as we potentially pursue additional indications,\u201d the filing says. \u201cWe may also incur expenses in connection with third-party trials involving our TCM formula or other intellectual property. In addition, if we obtain marketing approval for any of our TCM formula, we may initially incur significant outsourced sales, marketing and manufacturing expenses, as well as continued research and development expenses. As a result, we expect to continue to incur increasing operating losses for the foreseeable future<\/strong>.\u201d<\/p>\n\n\n\n

38-for-1 stock split boosts stock price<\/span><\/h2>\n\n\n\n

Despite its lack of revenue and earnings, the stock price has gone through the roof, rising some 17,000% in 2025 to $23 per share<\/strong>. Here\u2019s how it got there.<\/p>\n\n\n\n

Regencell has what is called a low public float<\/strong>, meaning there are very few publicly available shares. The founder and CEO, Yat-Gai Au owns 88.6% of the shares and company insiders own about 89% of the outstanding shares \u2013 so only about 56 million of the 494 million outstanding shares are available in the public float<\/strong>.<\/p>\n\n\n\n

This was one of the reasons that the stock drove so much higher. It took off due to several factors<\/strong>, including algorithmic trading and AI bots, which may have flagged it for its low float. It also surged from buzz on social media sites about the promise of its mission of using traditional Chinese medicine for ADHD and ASD and some early trials.<\/p>\n\n\n\n

The share price had risen to about $595 per share in June of this year, and then another catalyst hit \u2013 a 38-for-1 stock split<\/strong>. That means for every share owned, the shareholder would get 38 shares priced at $16 per share. <\/p>\n\n\n\n

The split made the stock cheaper to buy and that generated excitement around the stock as more investors bought in. This jolted the stock split price of $16 per share up to more than $70 per share in mid-June. The stock price soon crashed back down, but it mostly stayed in the $14 per share to $17 per share range until a recent surge brought it up to its current $23 per share price.<\/p>\n\n\n\n

It should be noted that the company is being investigated by the<\/strong> US Department of Justice<\/strong> \u201cinto the trading in our ordinary shares. The DOJ has requested the production of documents and communications concerning these and other corporate operational, financial and accounting matters. We are cooperating with this investigation, but we cannot predict its ultimate resolution,\u201d the filing said.<\/p>\n\n\n\n

It has certainly been a wild ride for Regencell, but investors should be extremely cautious<\/strong> given its lack of revenue or earnings, its volatile nature, and its lack of analyst coverage \u2013 in addition to the DOJ probe.<\/p>\n","protected":false},"excerpt":{"rendered":"

One of the most interesting and incredible stories of 2025 was the meteoric rise of a pharma stock with no revenue. <\/p>\n","protected":false},"author":22188,"featured_media":2589357,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[668623,10463],"tags":[665031,669104,660155],"states":[],"class_list":["post-2589356","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-stocks","tag-pharma-companies","tag-pharmaceutical-stocks","tag-regencell-bioscience-limited","entry"],"acf":[],"yoast_head":"\nHow This Stock with No Revenue Returned More Than 17,000%<\/title>\n<meta name=\"description\" content=\"One of the most interesting and incredible stories of 2025 was the meteoric rise of a pharma stock with no revenue.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.valuewalk.com\/news\/how-this-stock-with-no-revenue-returned-more-than-17000\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"How This Stock with No Revenue Returned More Than 17,000%\" \/>\n<meta property=\"og:description\" content=\"One of the most interesting and incredible stories of 2025 was the meteoric rise of a pharma stock with no revenue.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.valuewalk.com\/news\/how-this-stock-with-no-revenue-returned-more-than-17000\/\" \/>\n<meta property=\"og:site_name\" content=\"ValueWalk\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/valuewalk\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-23T17:05:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-24T19:05:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.valuewalk.com\/wp-content\/uploads\/2025\/12\/shockedwowsurprised_1280x720-150x150.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"720\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Dave Kovaleski\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@valuewalk\" \/>\n<meta name=\"twitter:site\" content=\"@valuewalk\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dave Kovaleski\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/www.valuewalk.com\/news\/how-this-stock-with-no-revenue-returned-more-than-17000\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.valuewalk.com\/news\/how-this-stock-with-no-revenue-returned-more-than-17000\/\"},\"author\":{\"name\":\"Dave Kovaleski\",\"@id\":\"https:\/\/www.valuewalk.com\/#\/schema\/person\/7b67e7959830798f982765793c7c41ee\"},\"headline\":\"How This Stock with No Revenue Returned More Than 17,000%\",\"datePublished\":\"2025-12-23T17:05:05+00:00\",\"dateModified\":\"2025-12-24T19:05:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.valuewalk.com\/news\/how-this-stock-with-no-revenue-returned-more-than-17000\/\"},\"wordCount\":655,\"publisher\":{\"@id\":\"https:\/\/www.valuewalk.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.valuewalk.com\/news\/how-this-stock-with-no-revenue-returned-more-than-17000\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.valuewalk.com\/wp-content\/uploads\/2025\/12\/shockedwowsurprised_1280x720.jpg\",\"keywords\":[\"pharma companies\",\"pharmaceutical stocks\",\"Regencell Bioscience Limited\"],\"articleSection\":[\"News\",\"Stocks\"],\"inLanguage\":\"en-US\",\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\/\/www.valuewalk.com\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.valuewalk.com\/news\/how-this-stock-with-no-revenue-returned-more-than-17000\/\",\"url\":\"https:\/\/www.valuewalk.com\/news\/how-this-stock-with-no-revenue-returned-more-than-17000\/\",\"name\":\"How This Stock with No Revenue Returned More Than 17,000%\",\"isPartOf\":{\"@id\":\"https:\/\/www.valuewalk.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.valuewalk.com\/news\/how-this-stock-with-no-revenue-returned-more-than-17000\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.valuewalk.com\/news\/how-this-stock-with-no-revenue-returned-more-than-17000\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.valuewalk.com\/wp-content\/uploads\/2025\/12\/shockedwowsurprised_1280x720.jpg\",\"datePublished\":\"2025-12-23T17:05:05+00:00\",\"dateModified\":\"2025-12-24T19:05:44+00:00\",\"description\":\"One of the most interesting and incredible stories of 2025 was the meteoric rise of a pharma stock with no revenue.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.valuewalk.com\/news\/how-this-stock-with-no-revenue-returned-more-than-17000\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.valuewalk.com\/news\/how-this-stock-with-no-revenue-returned-more-than-17000\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.valuewalk.com\/news\/how-this-stock-with-no-revenue-returned-more-than-17000\/#primaryimage\",\"url\":\"https:\/\/www.valuewalk.com\/wp-content\/uploads\/2025\/12\/shockedwowsurprised_1280x720.jpg\",\"contentUrl\":\"https:\/\/www.valuewalk.com\/wp-content\/uploads\/2025\/12\/shockedwowsurprised_1280x720.jpg\",\"width\":1280,\"height\":720},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.valuewalk.com\/news\/how-this-stock-with-no-revenue-returned-more-than-17000\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.valuewalk.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\",\"item\":\"https:\/\/www.valuewalk.com\/news\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"How This Stock with No Revenue Returned More Than 17,000%\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.valuewalk.com\/#website\",\"url\":\"https:\/\/www.valuewalk.com\/\",\"name\":\"Valuewalk\",\"description\":\"ValueWalk provides unique coverage on the stock market, cryptocurrencies, and personal finance space.\",\"publisher\":{\"@id\":\"https:\/\/www.valuewalk.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.valuewalk.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.valuewalk.com\/#organization\",\"name\":\"ValueWalk\",\"url\":\"https:\/\/www.valuewalk.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.valuewalk.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.valuewalk.com\/wp-content\/uploads\/2024\/06\/favicon_dark.svg\",\"contentUrl\":\"https:\/\/www.valuewalk.com\/wp-content\/uploads\/2024\/06\/favicon_dark.svg\",\"width\":32,\"height\":32,\"caption\":\"ValueWalk\"},\"image\":{\"@id\":\"https:\/\/www.valuewalk.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/valuewalk\/\",\"https:\/\/x.com\/valuewalk\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.valuewalk.com\/#\/schema\/person\/7b67e7959830798f982765793c7c41ee\",\"name\":\"Dave Kovaleski\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.valuewalk.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/www.valuewalk.com\/wp-content\/uploads\/2024\/02\/IMG-1696-96x96.jpg\",\"contentUrl\":\"https:\/\/www.valuewalk.com\/wp-content\/uploads\/2024\/02\/IMG-1696-96x96.jpg\",\"caption\":\"Dave Kovaleski\"},\"description\":\"Dave is a senior writer at ValueWalk, covering and analyzing stocks and ETFs across most sectors. Before joining ValueWalk, Dave was a writer\/analyst at The Motley Fool, where he mainly covered financials, consumer goods, market movers, and technology stocks. Dave has also written about personal finance for Standard & Poor's, money markets for Crane Data, financial regulations for Macallan Communications, and institutional investments for Pensions & Investments. His articles have appeared in USA Today, Yahoo Finance, Nasdaq, MSN, Fox Business, and in newspapers across the country. He has also written two local history books in his native Massachusetts.\",\"sameAs\":[\"http:\/\/linkedin.com\/in\/dave-kovaleski-a940a31\/\",\"https:\/\/x.com\/valuewalk\"],\"url\":\"https:\/\/www.valuewalk.com\/author\/davekovaleski\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"How This Stock with No Revenue Returned More Than 17,000%","description":"One of the most interesting and incredible stories of 2025 was the meteoric rise of a pharma stock with no revenue.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.valuewalk.com\/news\/how-this-stock-with-no-revenue-returned-more-than-17000\/","og_locale":"en_US","og_type":"article","og_title":"How This Stock with No Revenue Returned More Than 17,000%","og_description":"One of the most interesting and incredible stories of 2025 was the meteoric rise of a pharma stock with no revenue.","og_url":"https:\/\/www.valuewalk.com\/news\/how-this-stock-with-no-revenue-returned-more-than-17000\/","og_site_name":"ValueWalk","article_publisher":"https:\/\/www.facebook.com\/valuewalk\/","article_published_time":"2025-12-23T17:05:05+00:00","article_modified_time":"2025-12-24T19:05:44+00:00","og_image":[{"width":1280,"height":720,"url":"https:\/\/www.valuewalk.com\/wp-content\/uploads\/2025\/12\/shockedwowsurprised_1280x720-150x150.jpg","type":"image\/jpeg"}],"author":"Dave Kovaleski","twitter_card":"summary_large_image","twitter_creator":"@valuewalk","twitter_site":"@valuewalk","twitter_misc":{"Written by":"Dave Kovaleski","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/www.valuewalk.com\/news\/how-this-stock-with-no-revenue-returned-more-than-17000\/#article","isPartOf":{"@id":"https:\/\/www.valuewalk.com\/news\/how-this-stock-with-no-revenue-returned-more-than-17000\/"},"author":{"name":"Dave Kovaleski","@id":"https:\/\/www.valuewalk.com\/#\/schema\/person\/7b67e7959830798f982765793c7c41ee"},"headline":"How This Stock with No Revenue Returned More Than 17,000%","datePublished":"2025-12-23T17:05:05+00:00","dateModified":"2025-12-24T19:05:44+00:00","mainEntityOfPage":{"@id":"https:\/\/www.valuewalk.com\/news\/how-this-stock-with-no-revenue-returned-more-than-17000\/"},"wordCount":655,"publisher":{"@id":"https:\/\/www.valuewalk.com\/#organization"},"image":{"@id":"https:\/\/www.valuewalk.com\/news\/how-this-stock-with-no-revenue-returned-more-than-17000\/#primaryimage"},"thumbnailUrl":"https:\/\/www.valuewalk.com\/wp-content\/uploads\/2025\/12\/shockedwowsurprised_1280x720.jpg","keywords":["pharma companies","pharmaceutical stocks","Regencell Bioscience Limited"],"articleSection":["News","Stocks"],"inLanguage":"en-US","copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/www.valuewalk.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/www.valuewalk.com\/news\/how-this-stock-with-no-revenue-returned-more-than-17000\/","url":"https:\/\/www.valuewalk.com\/news\/how-this-stock-with-no-revenue-returned-more-than-17000\/","name":"How This Stock with No Revenue Returned More Than 17,000%","isPartOf":{"@id":"https:\/\/www.valuewalk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.valuewalk.com\/news\/how-this-stock-with-no-revenue-returned-more-than-17000\/#primaryimage"},"image":{"@id":"https:\/\/www.valuewalk.com\/news\/how-this-stock-with-no-revenue-returned-more-than-17000\/#primaryimage"},"thumbnailUrl":"https:\/\/www.valuewalk.com\/wp-content\/uploads\/2025\/12\/shockedwowsurprised_1280x720.jpg","datePublished":"2025-12-23T17:05:05+00:00","dateModified":"2025-12-24T19:05:44+00:00","description":"One of the most interesting and incredible stories of 2025 was the meteoric rise of a pharma stock with no revenue.","breadcrumb":{"@id":"https:\/\/www.valuewalk.com\/news\/how-this-stock-with-no-revenue-returned-more-than-17000\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.valuewalk.com\/news\/how-this-stock-with-no-revenue-returned-more-than-17000\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.valuewalk.com\/news\/how-this-stock-with-no-revenue-returned-more-than-17000\/#primaryimage","url":"https:\/\/www.valuewalk.com\/wp-content\/uploads\/2025\/12\/shockedwowsurprised_1280x720.jpg","contentUrl":"https:\/\/www.valuewalk.com\/wp-content\/uploads\/2025\/12\/shockedwowsurprised_1280x720.jpg","width":1280,"height":720},{"@type":"BreadcrumbList","@id":"https:\/\/www.valuewalk.com\/news\/how-this-stock-with-no-revenue-returned-more-than-17000\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.valuewalk.com\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/www.valuewalk.com\/news\/"},{"@type":"ListItem","position":3,"name":"How This Stock with No Revenue Returned More Than 17,000%"}]},{"@type":"WebSite","@id":"https:\/\/www.valuewalk.com\/#website","url":"https:\/\/www.valuewalk.com\/","name":"Valuewalk","description":"ValueWalk provides unique coverage on the stock market, cryptocurrencies, and personal finance space.","publisher":{"@id":"https:\/\/www.valuewalk.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.valuewalk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.valuewalk.com\/#organization","name":"ValueWalk","url":"https:\/\/www.valuewalk.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.valuewalk.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.valuewalk.com\/wp-content\/uploads\/2024\/06\/favicon_dark.svg","contentUrl":"https:\/\/www.valuewalk.com\/wp-content\/uploads\/2024\/06\/favicon_dark.svg","width":32,"height":32,"caption":"ValueWalk"},"image":{"@id":"https:\/\/www.valuewalk.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/valuewalk\/","https:\/\/x.com\/valuewalk"]},{"@type":"Person","@id":"https:\/\/www.valuewalk.com\/#\/schema\/person\/7b67e7959830798f982765793c7c41ee","name":"Dave Kovaleski","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.valuewalk.com\/#\/schema\/person\/image\/","url":"https:\/\/www.valuewalk.com\/wp-content\/uploads\/2024\/02\/IMG-1696-96x96.jpg","contentUrl":"https:\/\/www.valuewalk.com\/wp-content\/uploads\/2024\/02\/IMG-1696-96x96.jpg","caption":"Dave Kovaleski"},"description":"Dave is a senior writer at ValueWalk, covering and analyzing stocks and ETFs across most sectors. Before joining ValueWalk, Dave was a writer\/analyst at The Motley Fool, where he mainly covered financials, consumer goods, market movers, and technology stocks. Dave has also written about personal finance for Standard & Poor's, money markets for Crane Data, financial regulations for Macallan Communications, and institutional investments for Pensions & Investments. His articles have appeared in USA Today, Yahoo Finance, Nasdaq, MSN, Fox Business, and in newspapers across the country. He has also written two local history books in his native Massachusetts.","sameAs":["http:\/\/linkedin.com\/in\/dave-kovaleski-a940a31\/","https:\/\/x.com\/valuewalk"],"url":"https:\/\/www.valuewalk.com\/author\/davekovaleski\/"}]}},"modified_by":"Dave Kovaleski","_links":{"self":[{"href":"https:\/\/www.valuewalk.com\/wp-json\/wp\/v2\/posts\/2589356","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.valuewalk.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.valuewalk.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.valuewalk.com\/wp-json\/wp\/v2\/users\/22188"}],"replies":[{"embeddable":true,"href":"https:\/\/www.valuewalk.com\/wp-json\/wp\/v2\/comments?post=2589356"}],"version-history":[{"count":2,"href":"https:\/\/www.valuewalk.com\/wp-json\/wp\/v2\/posts\/2589356\/revisions"}],"predecessor-version":[{"id":2589397,"href":"https:\/\/www.valuewalk.com\/wp-json\/wp\/v2\/posts\/2589356\/revisions\/2589397"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.valuewalk.com\/wp-json\/wp\/v2\/media\/2589357"}],"wp:attachment":[{"href":"https:\/\/www.valuewalk.com\/wp-json\/wp\/v2\/media?parent=2589356"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.valuewalk.com\/wp-json\/wp\/v2\/categories?post=2589356"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.valuewalk.com\/wp-json\/wp\/v2\/tags?post=2589356"},{"taxonomy":"states","embeddable":true,"href":"https:\/\/www.valuewalk.com\/wp-json\/wp\/v2\/states?post=2589356"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}